Merck Eyes $32 Billion Revolution Medicines Takeover: The Keytruda Replacement Race Intensifies
Merck is in advanced talks to acquire Revolution Medicines for up to $32 billion as it races to replace blockbuster cancer drug Keytruda before patent expiration.